Paris, May 17th 2016 – Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces a successful €14.7m follow-on offering for Amoeba, producer of a biological biocide capable of eliminating waterborne bacterial risks. Bryan, Garnier & Co acted as Global Coordinator, Joint Lead Manager and Bookrunner, strengthening its leadership position in the Cleantech & Renewables sector.
A total of 544,215 new ordinary shares, have been issued to qualified and institutional investors in the United States and Europe of which two third are from France and one third are aboard. The new shares represent the maximum 10% capital authorization prior to the private placement. The transaction was oversubscribed with over 40 institutional investors.
The net proceeds from the transaction will be used primarily for financing: i) the acceleration of operations in Europe following (a) the deployment of two production units and (b) the development of the North American market through the implementation of a production unit in order to facilitate, in particular, the completion of the research and development (R&D) tests in Canada, and ii) general corporate expenses.
Olivier Beaudouin, Partner leading the Cleantech & Renewables franchise commented: “Amoeba is the top performing IPO in Europe since January 2015 (+282%). This follow-on offering was substantially oversubscribed with solid, quality demand in France, in Europe and in the US. This success demonstrates our commitment to our client on and after their IPO, our international placement capabilities, and strengthens our position as advisor to European Cleantech companies.”
For more information, please contact:
Partner –Corporate Finance – Technology & Cleantech
firstname.lastname@example.org | + 33 1 56 68 75 35
Director – Equity Capital Markets
email@example.com | + 33 1 56 68 75 30
Director – Corporate Finance
firstname.lastname@example.org | + 33 1 70 36 57 15
About Amoeba (www.amoeba-biocide.com)
Based in Chassieu – France, AMOEBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.) This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector. AMOEBA is continuing with its regulatory procedures so as to launch the request for provisional MA in the first half of 2016 for all European countries, as soon as ANSES (French Agency for Food, Environmental and Occupational Health & Safety) has validated AMOEBA’s solution for the “Air Cooled Towers” application. In a worldwide market for chemical biocides, estimated to be worth EUR 21 bn, AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT) estimated to be worth EUR 1.7 bn. Its disruptive technology complies with new regulations in terms of chemical emissions into the environment. AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC Small index last September 21. For more information: www.amoeba-biocide.com.
About Bryan, Garnier & Co (www.bryangarnier.com)
Bryan, Garnier & Co is an independent investment bank specialized in European growth companies, providing them with Equity Research & Brokerage, Asset Management and Corporate Finance services. With more than 150 professionals throughout London, Paris, Munich, New York, Geneva and New Delhi, Bryan, Garnier & Co combines the range of services and the expertise of top-tier investment banks with the level of attention to clients of a boutique. Bryan, Garnier & Co is a leading advisor to European growth companies on strategic finance transactions such as mergers & acquisitions, equity capital markets, LBOs and private placements. Bryan, Garnier & Co is authorized and regulated by the Financial Conduct Authority (FCA) in the United Kingdom, and is member of London Stock Exchange and Euronext, Alternext Listing Sponsor, and is active on all European capital markets.